Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2022-08-29 00:00:00 ET · period of report 2022-08-26 · accession 0001209191-22-047887 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-29 | 2022-08-26 | VNDA | Birznieks Gunther | SVP, Business Development | M - OptEx | $3.12 | +1,250 | 190.1K | +0.7% | +$3,900 |
| D | 2022-08-29 | 2022-08-26 | VNDA | Birznieks Gunther | SVP, Business Development | M - OptEx | $0.00 | -1,250 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-26 | M | A | 1,250 | $3.12 | 190,057 | D | — | — | |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2022-08-26 | M | D | 1,250 | $0.00 | 0 | D | $3.12 · — to 2022-12-06 | 1,250 Common Stock | (F1) The option vested in 48 equal monthly installments beginning on December 7, 2012. |